At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 96 enrolled
Drug / intervention
Prazosin +1 moredrug
Likely dose
Prazosin 16mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).
In Brief
A Phase 3 clinical trial evaluating Prazosin and Placebo for Alcohol Dependence and Stress Disorders, Post-Traumatic. Completed, enrolled 96 participants across 1 site.
Detailed Summary
Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence. The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and PTSD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2008
Enrollment StartJan 2009
Primary CompletionOct 2014
TodayJul 2026
First PostedAug 29, 2008
Enrollment StartJan 1, 2009
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 17.8 years ago
Interventions
Prazosindrug
prazosin (16mg/day) 2 times a day
Placebodrug
Placebo